Extracorporeal Membrane Oxygenation in Coronavirus Disease (COVID-19), Influenza and ARDS of Other Ethiologies

Study Overview
=================
Brief Summary
-----------------
A comparison of clinical characteristics and outcomes of patients on extracorporeal membrane oxygenation (ECMO) in COVID-19, influenza and ARDS of other ethiologies

Detailed Description
-----------------
All ARDS patients on extracorporeal membrane oxygenation (ECMO) during January 1st 2016 and January 10th 2022 in University Medical Center Ljubljana were included and their clinical characteristics and outcomes were studied according to ARDS ethiology: COVID-19, influenza and other ethiologies.

Official Title
-----------------
Extracorporeal Membrane Oxygenation in COVID-19, Influenza and ARDS of Other Ethiologies

Conditions
-----------------
ARDS, COVID-19, Influenza

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) 18 years or older Exclusion Criteria: Patient not eligible for ECMO treatment per institutional guidelines (terminal illness, palliative care)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 ARDS<br>Patients with COVID-19 ARDS on veno-venous ECMO (vvECMO) | |
| Influenza ARDS<br>Patients with Influenza ARDS on vvECMO | |
| ARDS of Other Ethiologies<br>Patients with ARDS of Other Ethiologies on vvECMO | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 180-day survival | 180-day survival from ECMO implantation | From day of ECMO-implant for every 24 hours until date of death or survival at 180 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Days on ECMO | Days on ECMO from ECMO implantation | From day of ECMO-implant for every 24 hours until date of weaning or death | 
| Weaning from ECMO | Weaning from ECMO | From day of ECMO-implant until date of death or weaning | 
| ICU length of stay | ICU length of stay from ECMO implantation | From day of ICU-admission for every 24 hours until date of death or date of ICU discharge | 
| ICU survival | ICU survival from ECMO implantation | From day of ICU-admission for every 24 hours until date of death or survival at ICU discharge | 
| Hospital survival | Hospital survival from ECMO implantation | From day of hospital admission for every 24 hours until date of death or survival at hospital discharge | 
| 30-day survival | 30-day survival from ECMO implantation | From day of ECMO-implant for every 24 hours until date of death or survival at 30 days | 
| 90-day survival | 90-day survival from ECMO implantation | From day of ECMO-implant for every 24 hours until date of death or survival at 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Extracorporeal Membrane Oxygenation, ARDS, COVID-19, Influenza